NEW YORK (GenomeWeb News) – Qiagen today announced it and the Bio-X Center of Shanghai Jiao Tong University will jointly create a translational medicine laboratory in Shanghai.
The lab, which is the first of its kind between Qiagen and a major research institution in China, will be outfitted with Qiagen's Pyromark Q24MDx pyrosequencing instrument and QIAcube instruments, as well as related products. Bio-X Center will use the products in various research projects including biomarker validation and analysis.
"Through this agreement with the Bio-X Center we can leverage our leading positions as a solutions provider in biological research, drug discovery, and personalized healthcare to help develop better diagnostics and therapies for the Chinese people," Victor Shi, Asia Pacific president of Qiagen, said in a statement.
Though the deal is Qiagen's first in China creating a translational medicine lab, the company has forged other deals in Asia. In 2007, it opened a subsidiary in Hong Kong to be a hub for further expansion in the region. The same year, Qiagen formed a joint venture with Bio*One Capital in Singapore focused on developing molecular diagnostic assays.